QMS Medical Allied Services LimitedPharmaceuticals & HealthcareQMSMEDI
Q1 FY27 concall · earnings callQMS Medical Allied Services Limited
Q1 FY27 saw strong revenue and profit growth driven by scaling service business (Patient Support Programs) and strategic investments beginning to yield results.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated Revenue | ₹56.9 Cr | +22% YoY growth | |
| EBITDA | ₹8.3 Cr | +27% YoY growth | |
| EBITDA Margin | 14.6% | Improvement vs 14.1% in Q1 FY26 and 13.3% in Q4 FY26 | |
| PAT | ₹4 Cr | +25% YoY growth | |
| PAT Margin | 7% | Improvement | |
| PSP Revenue | ₹17.6 Cr | — | |
| B2B Camps Conducted | 11,497 | ~40% increase over last quarter |
TL;DR
- Revenue grew 22% YoY to INR56.9 crores; EBITDA grew 27% YoY to INR8.3 crores; PAT grew 25% YoY to ~INR4 crores.
- Service revenue (PSP + camps) contributed ~40% of total revenue in Q1, up from 30% a year ago.
- PSP business, including subsidiary Saarathi, generated ~INR17.6 crores revenue in Q1; targeting INR90-100 crores service revenue visibility for FY27.
- Q Devices revenue was ~INR3 crores in Q1; targeting 20-25% of total product revenue from Q Devices in 3 years.
- Management maintains FY27 revenue guidance of ~INR220 crores and EBITDA margin guidance of ~18%.
Said on the call
“I believe these numbers are particularly important because they demonstrate that the investments we made during the FY '26 in people, technology, infrastructure and service capabilities are now beginning to translate into a strong revenue growth and improved operational performance.”
From the Q&A
| Topic | What management said |
|---|---|
| Q Devices Performance and Target | Q1 revenue was ~INR3 crores; targeting 10-15% revenue contribution in FY27 and 20-25% of product revenue in 3 years. |
| Employee Cost Increase | Increased due to hiring for long-term PSP contracts; cost is charged to clients; current run rate is seen as stable. |
| Gross Margin Expansion Driver | Higher contribution from services (40% of revenue vs 30% YoY) drove gross margin improvement. |
| FY27 Service Revenue Guidance | Visibility of INR90-100 crores for the year from services (PSP + camps). |
| PSP Contract Stickiness and Growth | Contracts are typically annual with 60-70% renewal rates; growth levers are renewals, program expansion, and new pipeline wins. |
| EBITDA Margin Guidance for FY27 | Management maintains ~18% EBITDA margin guidance based on current projections and ramp-up plans. |
Guidance
- Maintain FY27 revenue guidance of ~INR220 crores.
- Maintain FY27 EBITDA margin guidance of ~18%.
- Service revenue visibility of INR90-100 crores for FY27.
- Aiming to acquire remaining 24% stake in Saarathi Healthcare by end of Q2 FY27.
Source
Summary written from the transcript filed by QMS Medical Allied Services Limited for the call held on 17 Aug 2026; published 21 Aug 2026, 16:56 IST.
More Q1 FY27 concalls ·How verification works ·Report an error